Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
William Valentine, Kirsi Norrbacka & Kristina Secnik Boye. (2022) Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes. Patient Related Outcome Measures 13, pages 97-111.
Read now
Read now
Kristina S. Boye, Louis S. Matza, Katie D. Stewart, Haylee Andrews, Timothy A. Howell, Adam Stefanski, Karen G. Malley, K. Jack Ishak & Laura Fernández Landó. (2022) Health state utilities associated with weight loss in type 2 diabetes and obesity. Journal of Medical Economics 25:1, pages 14-25.
Read now
Read now
Heather L Gelhorn, Kristina S Boye, Huda Shalhoub, Louis S Matza, Jessica B Jordan, Ali Alhammad, Savita B Anand, Aishah A Ekhzaimy & Alena Strizek. (2020) Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia. Patient Preference and Adherence 14, pages 2231-2242.
Read now
Read now
Richard A Chudleigh, Julia Platts & Stephen C Bain. (2020) Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data. Diabetes, Metabolic Syndrome and Obesity 13, pages 433-438.
Read now
Read now
Richard A Chudleigh & Stephen C Bain. (2020) Semaglutide injection for the treatment of adults with type 2 diabetes. Expert Review of Clinical Pharmacology 13:7, pages 675-684.
Read now
Read now
Articles from other publishers (10)
Kristina S. Boye, Jessica B. Jordan, Raleigh Malik & Louis S. Matza. (2023) Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States. Diabetes Therapy.
Crossref
Crossref
Yuqiong Lu, Zhanjing Dai, Feng Chang, Li Wang, Jiafang He, Penghua Shi, Haitao Zhang & Yun Lu. (2023) Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment. PharmacoEconomics 41:3, pages 295-306.
Crossref
Crossref
Phil McEwan, James Baker-Knight, Björg Ásbjörnsdóttir, Yunni Yi, Aimee Fox & Robin Wyn. (2022) Disutility of injectable therapies in obesity and type 2 diabetes mellitus: general population preferences in the UK, Canada, and China. The European Journal of Health Economics 24:2, pages 187-196.
Crossref
Crossref
Louis S. Matza, Timothy A. Howell, Vasiliki Chounta & Nicolas van de Velde. (2022) Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV. Quality of Life Research 32:2, pages 531-541.
Crossref
Crossref
Meredith Hoog, Joseph L. Smith, Maria Yu, Jennifer Peleshok, Reema Mody & Michael Grabner. (2022) Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States. Clinical Therapeutics 44:6, pages 873-887.
Crossref
Crossref
José Gerardo González-González, Alejandro Díaz González-Colmenero, Juan Manuel Millán-Alanís, Lyubov Lytvyn, Ricardo Cesar Solis, Reem A Mustafa, Suetonia C Palmer, Sheyu Li, Qiukui Hao, Neri Alejandro Alvarez-Villalobos, Per Olav Vandvik & René Rodríguez-Gutiérrez. (2021) Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review. BMJ Open 11:7, pages e049130.
Crossref
Crossref
Louis S. Matza, Katelyn N. Cutts, Katie D. Stewart, Kirsi Norrbacka, Luis-Emilio García-Pérez & Kristina S. Boye. (2021) Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research 30:7, pages 2033-2043.
Crossref
Crossref
Sarah Zimner Rapuch, Victoria Divino, Kirsi Norrbacka, Kristina Boye, Jeremie Lebrec, Myriam Rosilio, Mitch DeKoven & Bruno Guerci. (2021) Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. Diabetes Therapy 12:5, pages 1553-1567.
Crossref
Crossref
Kristina S. Boye, Hélène Sapin, Luis-Emilio García-Pérez, Myriam Rosilio, Marco Orsini Federici, Elke Heitmann, Heike Jung, Ulrich Aigner, Bruno Guerci, Francesco Giorgino & Kirsi Norrbacka. (2020) The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes. Diabetes Therapy 11:10, pages 2383-2399.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref